GetTopicDetailResponse(id=5c811058084, topicName=KSI-301, introduction=KSI-301, content=null, image=null, comments=4, allHits=1231, url=https://h5.medsci.cn/topic?id=10580, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=92686, tagList=[TagDto(tagId=92686, tagName=KSI-301)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1515304, encodeId=387b15153045f, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=濕性AMD藥物KSI-301在臨床試驗中并不優(yōu)于Eylea (aflibercept), objectType=article, longId=299741, objectId=beb8299e4190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beb8299e4190, replyNumber=0, likeNumber=86, createdTime=2022-03-01, rootId=0, userName=12498aa2m65(暫無昵稱), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beb8299e4190, moduleTitle=濕性AMD藥物KSI-301在臨床試驗中并不優(yōu)于Eylea (aflibercept), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=beb8299e4190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515303, encodeId=933715153030d, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=KSI-301治療濕性AMD、糖尿病性黃斑水腫和視網膜靜脈阻塞的Ib期臨床試驗取得積極結果, objectType=article, longId=187876, objectId=f10618e87660, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f10618e87660, replyNumber=0, likeNumber=111, createdTime=2020-02-13, rootId=0, userName=12498aa2m65(暫無昵稱), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f10618e87660, moduleTitle=KSI-301治療濕性AMD、糖尿病性黃斑水腫和視網膜靜脈阻塞的Ib期臨床試驗取得積極結果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f10618e87660)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515302, encodeId=01a91515302b0, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=2019年視網膜協(xié)會年會：抗體生物聚合物共軛物（ABC）KSI-301治療濕性AMD, objectType=article, longId=179538, objectId=2f8c1e95381c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f8c1e95381c, replyNumber=0, likeNumber=89, createdTime=2019-09-18, rootId=0, userName=12498aa2m65(暫無昵稱), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f8c1e95381c, moduleTitle=2019年視網膜協(xié)會年會：抗體生物聚合物共軛物（ABC）KSI-301治療濕性AMD, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2f8c1e95381c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515301, encodeId=b923151530169, content=<a href='/topic/show?id=5c811058084' target=_blank style='color:#2F92EE;'>#KSI-301#</a>, objectTitle=新型抗VEGF抗體聚合物KSI-301治療濕性AMD、DME、RVO取得階段成果, objectType=article, longId=176439, objectId=b2ea1e643956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ea1e643956, replyNumber=0, likeNumber=107, createdTime=2019-07-31, rootId=0, userName=12498aa2m65(暫無昵稱), userId=96a910754704, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ea1e643956, moduleTitle=新型抗VEGF抗體聚合物KSI-301治療濕性AMD、DME、RVO取得階段成果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b2ea1e643956)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
